Table 2.

Treatment and outcomes of the regdanvimab and supportive care groups, total cohort.

Variables	Regdanvimab (n = 1,095)	Supportive care (n = 1,119)	P value
Regdanvimab
Regdanvimab treatment	1,095 (100)	0 (0.0)	NA
Interval from symptom onset to regdanvimab, days	3.6 ± 2.0	NA	NA
Interval from admission to regdanvimab, days	1.1 ± 1.3	NA	NA
Remdesivir, steroid, and antibiotics
Remdesivir treatment	128 (11.7)	151 (13.5)	0.201
Interval from admission to remdesivir, days	2.5 ± 2.1	3.3 ± 3.1	0.006
Steroid treatment	183 (16.7)	247 (22.1)	0.001
Interval from admission to steroid, days	2.5 ± 2.7	3.1 ± 3.1	0.042
Antibiotic treatment	50 (4.6)	74 (6.6)	0.036
Interval from admission to antibiotics, days	1.7 ± 2.1	4.2 ± 3.7	<0.001
Outcome measures
O2 supplementation via nasal prong	201 (18.4)	303 (27.1)	<0.001
Interval from admission to nasal prong, days	17.5 ± 7.4	16.1 ± 8.2	<0.001
Composite outcome for progression to severe disease	44 (4.0)	90 (8.0)	<0.001
Interval from admission to composite outcome, days	20.3 ± 3.4	19.7 ± 4.5	<0.001
O2 supplement via facial mask	10 (0.9)	34 (3.0)	<0.001
Interval from admission to facial mask, days	4 (3–5)	5 (3–7)	0.002
O2 supplement via HFNC	26 (2.4)	40 (3.6)	0.097
Interval from admission to HFNC, days	3 (1–5)	5 (2–7)	<0.001
Referral to tertiary care center	20 (1.8)	57 (5.1)	<0.001
Interval from admission to referral, days	4 (2–6)	5 (3–8)	0.001
Live discharge after recovery without referral	1075 (98.2)	1058 (94.5)	<0.001
Interval from admission to discharge, days	10.3 ± 3.7	12.3 ± 12.5	<0.001
In-hospital mortality during follow-up period	0 (0.0)	4 (0.4)	0.125

Data are expressed as the number (%) of patients, mean ± SD, or median (IQR) unless indicated otherwise.

NA, not applicable; HFNC, high flow nasal cannula; SD, standard deviation; IQR, interquartile range.